Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

Similar Items

• PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
  by: Chiao-En Wu, et al.
  Published: (2020-01-01)
• Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
  by: Marius Ilie, et al.
  Published: (2017-01-01)
• Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
  by: Wenjia SUN, et al.
  Published: (2021-01-01)
• Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
  by: Marius Ilie, et al.
  Published: (2017-01-01)
• PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
  by: Naoya Maekawa, et al.
  Published: (2021-02-01)